Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively advancing a portfolio of drugs through clinical trials, all intended for administration via its ZENEO system. This pipeline includes Sumatriptan for treating migraines and cluster headaches, Adrenaline for severe allergic reactions (anaphylactic shock), Hydrocortisone for acute adrenal insufficiency, Midazolam for managing epileptic seizures, Naloxone for opioid overdose, Apomorphine for temporary paralysis in Parkinson's patients, Methotrexate for rheumatoid arthritis, and Terbutaline for acute asthma attacks. Founded in 1997, the company maintains its operational base in Dijon, France.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is of fair value on EV/EBITDA.